reviewed april 2026|next review october 2026|88 physicians psi has verified|255 published studies
Melanotan II
Melanotan II is a non-selective melanocortin agonist (MC1R through MC5R) originally developed for UV-free tanning, producing simultaneous skin darkening, appetite suppression, and sexual function effects, with the FDA-approved derivative PT-141 (bremelanotide, Vyleesi) engineered to isolate the sexual function mechanism.
Evidence landscape: 255 published studies
255 published items. 4 human studies and 185 animal studies. The parent compound of the FDA-approved derivative PT-141 (bremelanotide).
- 4 Human
- 185 Animal
- 11 Reviews
- 55 Other research
Activates receptors MC1R through MC5R simultaneously, producing skin darkening (tanning), appetite suppression, and sexual arousal as parallel effects.
Reports of new or changing moles are common among users. Whether melanogenesis stimulation increases melanoma risk is an unresolved question.
The FDA-approved derivative PT-141 (bremelanotide, Vyleesi) was specifically engineered to isolate the sexual function effect while reducing melanogenic and non-selective activity.
PSI Assessment
One of the most widely used peptides in biohacking communities carries safety concerns that the community has systematically underreported. Melanotan II is a non-selective melanocortin agonist originally developed at the University of Arizona for skin cancer prevention through UV-free tanning. It activates receptors MC1R through MC5R, producing skin darkening, appetite suppression, and sexual arousal simultaneously. Reports of new or changing moles are common among users. The FDA-approved derivative PT-141 (bremelanotide, Vyleesi) was specifically engineered to isolate the sexual function effect while reducing the melanogenic and non-selective activity.
Non-selective melanocortin activation produces tanning, appetite suppression, and sexual function simultaneously. Reports of new or changing moles are common. PT-141 is the selective FDA-approved derivative.
The mechanism is non-selective melanocortin receptor agonism across five receptor subtypes. MC1R activation drives melanogenesis (skin darkening). MC3R and MC4R activation drive appetite suppression and sexual function. The non-selectivity is both the source of the compound's range of effects and its primary safety concern. PT-141 (bremelanotide) was developed specifically to reduce MC1R melanogenic activity while preserving MC4R sexual function effects, and received FDA approval in 2019.
What the evidence supports
Melanotan II activates MC1R through MC5R, producing documented effects on skin pigmentation, appetite, and sexual function in human studies. The melanocortin mechanism is well-characterized. PT-141 (bremelanotide), the selective derivative, received FDA approval in 2019 for hypoactive sexual desire disorder, validating the MC4R pathway. Reports of new or changing moles are documented in the literature.
What is not yet established
Long-term safety of non-selective melanocortin activation. Whether melanogenesis stimulation increases melanoma risk in susceptible individuals. Optimal dosing for specific effects given the non-selective receptor profile. Whether the mole changes represent a cosmetic concern or a cancer precursor.
Research Evidence
The findings below cover the tanning mechanism, the sexual function pathway that led to PT-141, and the safety concerns that define the risk profile.
Evidence by condition
Evidence dimensions across Melanotan II's investigated applications. Tanning and sexual function have the most data. Safety questions remain unresolved.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Tanning/Melanogenesis | ||||
| Sexual Dysfunction | ||||
| Appetite Suppression |
Phase I human data confirms that Melanotan II produces skin darkening through MC1R-mediated melanogenesis without UV exposure. The tanning effect is dose-dependent and reversible upon discontinuation. This was the original research purpose - reducing skin cancer risk through protective tanning.
The tanning mechanism works as designed. The safety question is whether chronic melanocyte stimulation carries risks that outweigh the photoprotective benefit.
MC3R and MC4R activation produces sexual arousal effects. This unexpected finding in early tanning trials led to the development of PT-141 (bremelanotide), which received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
The sexual function pathway is validated by PT-141's FDA approval. The selective derivative exists specifically because Melanotan II's non-selective profile makes it unsuitable for targeted sexual function treatment.
Reports of new or changing moles are documented in the literature and common among users. The non-selective melanocortin activation stimulates melanocyte proliferation and activity. Whether this represents a cosmetic concern or a melanoma precursor is an unresolved question.
The mole change reports are the primary safety concern. Causality between Melanotan II and melanoma has not been established, but chronic melanocyte stimulation is a theoretical risk factor.
4 Human|185 Animal|11 Reviews
View all 255 indexed studiesHow Melanotan II Works
Melanotan II is a cyclic heptapeptide that non-selectively activates melanocortin receptors MC1R through MC5R, producing simultaneous effects on skin pigmentation, appetite, and sexual function.
Melanotan II activates the same receptors that your body uses to darken skin in response to sun exposure. It tells melanocytes (pigment cells) to produce more melanin. The pigment that gives skin its color. But because it is non-selective, it also activates receptors involved in appetite (making you less hungry), sexual arousal (increasing desire), and nausea.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Melanotan II is a cyclic heptapeptide analog of alpha-MSH that non-selectively activates MC1R through MC5R. MC1R activation drives melanogenesis through tyrosinase activation and melanin production. MC3R and MC4R activation in the hypothalamus drives appetite suppression and sexual function. The non-selectivity produces all effects simultaneously. PT-141 (bremelanotide) was derived by structural modification to enhance MC4R selectivity and reduce MC1R melanogenic activity.
What is Melanotan II being studied for?
Researchers are studying Melanotan II across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Melanotan II overall. This means a compound can have human studies for one condition but only animal data for another.
Tanning/Melanogenesis
·Animal StudiesHuman studies confirm Melanotan II produces skin darkening through MC1R-mediated melanin stimulation without UV exposure. This was the original research purpose.
Limitations: Not FDA-approved for any indication. Reports of new or changing moles raise concern about melanocyte stimulation and theoretical melanoma risk.
Sexual Dysfunction
·Animal StudiesMC3R and MC4R activation produces sexual arousal effects documented in human studies. This effect led to the development of PT-141 (bremelanotide/Vyleesi), which is FDA-approved for HSDD.
Limitations: For sexual function, PT-141 is the FDA-approved, selectively designed alternative. Melanotan II's non-selective activation produces unnecessary side effects for this application.
Appetite Suppression
·Animal StudiesMC4R activation suppresses appetite. Weight loss effects are commonly reported by users.
Limitations: Not studied or approved for weight management. Multiple safer, FDA-approved options exist for appetite and weight management.
Safety and Regulatory Status
FDA Status: Not FDA-approved for any indication.
Availability: On the FDA Category 2 list, meaning licensed pharmacies cannot currently compound it - the compound is restricted from preparation by compounding pharmacies. Expected to remain restricted.
Safety Concerns: Reports of new or changing moles, nausea, facial flushing. Theoretical melanoma risk from chronic melanocyte stimulation is unresolved.
Significant safety concerns exist. Reports of new or changing moles, darkening of existing moles, and facial flushing are common. Nausea is a frequent side effect. Theoretical concern about melanoma risk from chronic melanocyte stimulation has not been resolved.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Melanotan II discussion.
Comparison and Related Research
Melanotan II is most often compared with PT-141 (selective MC4R, FDA-approved derivative) and kisspeptin (different sexual function mechanism).
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.First Phase I human safety trial of Melanotan II. Subcutaneous injections produced measurable skin darkening in fair-skinned volunteers. The study established initial human dosing parameters and documented side effects including nausea and facial flushing.Dorr RT et al., 1996 in Life Sci. View on PubMed
- 2.Double-blind, placebo-controlled crossover trial demonstrating that Melanotan II initiated erections in men with psychogenic erectile dysfunction. This study provided the first controlled human evidence for a central nervous system pathway for melanocortin-induced sexual function effects.Wessells H et al., 1998 in J Urol. View on PubMed
- 3.Comprehensive review by the research group that originally developed melanocortin analogs, summarizing the evidence for melanocortin-mediated sexual function effects in both men and women. The review traced the research path from initial animal observations to controlled human trials.Hadley ME et al., 2005 in Peptides. View on PubMed
- 4.Critical review examining the safety profile of melanotropic peptides including Melanotan II. Raised concerns about potential effects on existing moles and melanocytic nevi, and highlighted the lack of long-term safety data for unregulated use.Langan EA et al., 2010 in Br J Dermatol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.